| Identification | Back Directory | [Name]
CB-25 | [CAS]
869376-63-6 | [Synonyms]
CB-25
N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)undecanamide
Undecanamide, N-cyclopropyl-11-(3-hydroxy-5-pentylphenoxy)- | [Molecular Formula]
C25H41NO3 | [MDL Number]
MFCD09951898 | [MOL File]
869376-63-6.mol | [Molecular Weight]
403.6 |
| Chemical Properties | Back Directory | [Melting point ]
70.7 °C(Solv: chloroform (67-66-3); methanol (67-56-1)) | [Boiling point ]
594.7±30.0 °C(Predicted) | [density ]
1.03±0.1 g/cm3(Predicted) | [solubility ]
DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 50 mg/ml; Ethanol:PBS (pH 7.2) (1:2): 0.3 mg/ml | [form ]
A crystalline solid | [pka]
9.75±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Description]
CB-25 is a stable analog of Δ9-tetrahydrocannabinol (THC) and anandamide (AEA). It exhibits high affinity for the central cannabinoid (CB1) and peripheral cannabinoid (CB2) receptors with Ki values of 5.2 and 13 nM, respectively. CB-25 behaves as an inverse agonist for the CB1 receptor as assessed in a cyclic AMP (cAMP) functional assay. | [Uses]
CB-25 is a stable anandamide analog CB1 inverse agonist. | [References]
[1] ANTONELLA BRIZZI. Design, Synthesis, and Binding Studies of New Potent Ligands of Cannabinoid Receptors[J]. Journal of Medicinal Chemistry, 2005, 48 23: 7343-7350. DOI: 10.1021/jm0501533
[2] M G CASCIO. In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands[J]. British Journal of Pharmacology, 2009, 149 4: 431-440. DOI: 10.1038/sj.bjp.0706888 |
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Website: |
https://www.bocsci.com |
| Company Name: |
BOC Sciences
|
| Tel: |
16314854226 |
| Website: |
www.bocsci.com |
| Company Name: |
Shureli Biopharma Co.,Ltd
|
| Tel: |
0871-68355600 18787766125 |
| Website: |
www.chemicalbook.com/ShowSupplierProductsList1143315/0_EN.htm |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|